We retrospectively and inclusively reviewed the clinical records of patients seeking refractive error corrections at Zhongshan Ophthalmic Center (ZOC) between 2009 and 2017. Children seeking refractions at ZOC were derived mainly from school-based vision screening programs in Guangzhou and, less commonly, referral from other eye care clinics throughout the country (usually children with significant refractive errors). The vision screening in schoolchildren, particularly, tested uncorrected visual acuity (UCVA) annually and children with UCVA of 20/25 or worse in either eye were recommended for further ophthalmic examinations. For every child visiting ZOC, cycloplegic refraction and best corrected visual acuity (BCVA) were measured unless otherwise refused. Follow-up schedules were recommended at clinician discretion, usually every 6 or 12 months to detect changes in refraction and visual acuity.
At ZOC, cycloplegic refractions were mostly performed using 1% tropicamide or 1% cyclopentolate eye drops for children aged ≥8 years, or using 1% atropine ointment at the first visit of a child younger than 8 years and 1% tropicamide or 1% cyclopentolate at following visits. Considering the confounding impacts of the use of different cycloplegic agents, only cycloplegic refractions obtained using 1% tropicamide or 1% cyclopentolate were analyzed in our study. This approach was considered acceptable because cycloplegic refractions obtained using 1% tropicamide and 1% cyclopentolate have been proved to show no significant difference among schoolchildren with hyperopia.
25
To define a homogeneous group of children, we limited the initial age to be 6 (range, 5.5–6.4), 7 (range, 6.5–7.4), or 8 (range, 7.5–8.4) years. The first visit occurred between ages 6 to 8 years (inclusive) was defined as the initial visit, and visits thereafter were defined as follow-up visits. Eligible criteria were: having cycloplegic refraction measured at the age of 6, 7, or 8 years; presenting SE (calculated as spherical power plus 1/2 cylindrical power) ≥+2.00 D and interocular SE difference <1.00 D at the initial visit; being followed for a minimum of 2 years since the initial visit and having at least three records on cycloplegic refractions; absence of any other ocular conditions, including aphakia, strabismus, nystagmus, and amblyopia (for the age range in our study, satisfying the following: presence or a history of at least one amblyogenic factor; presenting BCVA ≤ 20/40 in either eye or an interocular difference in BCVA of two or more lines after wearing optimal optical correction for a minimum of three months; and no cause for reduced visual acuity suspected other than amblyopia); and absence of any concurrent systemic disorders, such as developmental delay. The study was approved by the ethics committee of Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou and conducted in accordance with the Declaration of Helsinki.